{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:19:44Z","timestamp":1786979984982,"version":"build-2736575974"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>It is uncertain whether modern iodine-based or gadolinium-based contrast media (CM) administration can lead to increased symptoms in patients with myasthenia gravis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search in Medline was conducted for studies describing the symptomatology of myasthenia gravis patients before and after receiving intravenous (IV) CM and having a matched control group of myasthenia gravis patients who did not receive IV CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three retrospective studies were selected with a total of 374 myasthenia gravis patients who received iodine-based CM and a total of 313 myasthenia gravis patients who underwent unenhanced CT and served as controls. Pooling of the data from the three retrospective studies showed that in 23 of 374 patients, increased symptoms after iodine-based CM administration were described (6.1%). Increased symptomatology also occurred in 11 of 313 patients after unenhanced CT (3.5%). When looking more deeply into the data of the three studies, conflicting results were found, as two articles did not find any relationship between CM and myasthenia gravis symptoms. The remaining study only found a significant increase in symptomatology within 1\u00a0day after CT scanning: seven patients (6.3%) in the contrast-enhanced CT group and one patient (0.6%) in the unenhanced CT group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is limited evidence on the relationship between CM and myasthenia gravis symptoms. In the vast majority of myasthenia gravis patients, CM are safe. Probably, in less than 5% of the patients, iodine-based CM administration may lead to increased severity of the symptoms within the first 24\u00a0h after administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance statement<\/jats:title>\n                    <jats:p>Be aware that intravenous administration of iodine-based contrast media can lead to an increase of symptoms in patients with myasthenia gravis within the first 24\u00a0h. This can probably happen in less than 5% of the patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:italic>\u2022 It is unclear whether modern contrast media can lead to increased symptoms in myasthenia gravis patients after intravenous administration.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>\u2022 There seems to be a small risk of increased myasthenia gravis symptoms within 24\u00a0h after intravenous administration of iodine-based contrast media, probably in less than 5% of the administrations.<\/jats:italic>\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:italic>\u2022 Gadolinium-based contrast media are safe for patients with myasthenia gravis.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-023-10463-z","type":"journal-article","created":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T22:02:19Z","timestamp":1702504939000},"page":"4561-4566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safe use of contrast media in myasthenia gravis: systematic review and updated European Society of Urogenital Radiology Contrast Media Safety Committee guidelines"],"prefix":"10.1007","volume":"34","author":[{"given":"Remy W. F.","family":"Geenen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giles","family":"Roditi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-France","family":"Bellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkel","family":"Brismar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Correas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona A.","family":"Dekkers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertraud","family":"Heinz-Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas H.","family":"Mahnken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart J.","family":"van der Molen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo C.","family":"Quattrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Radbuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sebasti\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Stacul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Romanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6890-671X","authenticated-orcid":false,"given":"Olivier","family":"Cl\u00e9ment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Contrast Media Safety Committee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"10463_CR1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581","journal-title":"N Engl J Med"},{"key":"10463_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/S0140-6736(83)92749-6","volume":"321","author":"N Canal","year":"1983","unstructured":"Canal N, Franceschi M (1983) Myasthenic crisis precipitated by iothalamic acid. Lancet 321:1288","journal-title":"Lancet"},{"key":"10463_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1212\/WNL.35.8.1219","volume":"35","author":"Y Chagnac","year":"1985","unstructured":"Chagnac Y, Hadani M, Goldhammer Y (1985) Myasthenic crisis after intravenous administration of iodinated contrast media. Neurology 35:1219\u20131220","journal-title":"Neurology"},{"key":"10463_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/BF02230893","volume":"7","author":"GP Anzola","year":"1986","unstructured":"Anzola GP, Capra R, Magoni M, Vignolo LA (1986) Myasthenic crisis during intravenous iodinated contrast medium injection. Ital J Neurol Sci 7:273","journal-title":"Ital J Neurol Sci"},{"key":"10463_CR5","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1212\/WNL.37.8.1400","volume":"37","author":"JH Frank","year":"1987","unstructured":"Frank JH, Cooper FJH, Black WC, Philips LH 2nd (1987) Iodinated contrast agents in myasthenia gravis. Neurology 37:1400\u20131402","journal-title":"Neurology"},{"key":"10463_CR6","first-page":"365","volume":"13","author":"B Bonmarchand","year":"1987","unstructured":"Bonmarchand B, Weiss P, Clavier E, Lerebours-Pigeonniere G, Massari P, Leroy J (1987) Myasthenic crisis following the injection of an iodinated contrast medium. Intensive Care Med 13:365","journal-title":"Intensive Care Med"},{"key":"10463_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/WNL.40.10.1623","volume":"40","author":"S Eliashiv","year":"1990","unstructured":"Eliashiv S, Wirguin I, Brenner T, Argov Z (1990) Aggravation of human and experimental myasthenia gravis by contrast media. Neurology 40:1623\u20131625","journal-title":"Neurology"},{"key":"10463_CR8","doi-asserted-by":"crossref","unstructured":"de Rocha MS, Bacheschi LA (1994) Exacerbation of myasthenia gravis by contrast media. AJR Am J Roentgenol 162:997","DOI":"10.2214\/ajr.162.4.8141034"},{"key":"10463_CR9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/0140-6736(92)93203-Y","volume":"340","author":"AM Nordenbo","year":"1992","unstructured":"Nordenbo AM, Somnier FE (1992) Acute deterioration of myasthenia gravis after intravenous administration of gadolinium-DTPA. Lancet 340:1168","journal-title":"Lancet"},{"key":"10463_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/ana.410190222","volume":"19","author":"P Van den Bergh","year":"1986","unstructured":"Van den Bergh P, Kelly JJ Jr, Carter B, Munsat TL (1986) Intravascular contrast media and neuromuscular junction disorders. Ann Neurol 19:206\u2013207","journal-title":"Ann Neurol"},{"key":"10463_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1148\/radiol.12121508","volume":"267","author":"DK Somashekar","year":"2013","unstructured":"Somashekar DK, Davenport MS, Cohan RH, Dillman JR, Ellis JH (2013) Effect of intravenous low-osmolality iodinated contrast media on patients with myasthenia gravis. Radiology 267:727\u2013734","journal-title":"Radiology"},{"key":"10463_CR12","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00415-017-8518-8","volume":"264","author":"J Rath","year":"2017","unstructured":"Rath J, Mauritz M, Zulehner G et al (2017) Iodinated contrast agents in patients with myasthenia gravis: a retrospective cohort study. J Neurol 264:1209\u20131217","journal-title":"J Neurol"},{"key":"10463_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/mus.24254","volume":"50","author":"M Mehrizi","year":"2014","unstructured":"Mehrizi M, Pascuzzi M (2014) Complications of radiologic contrast in patients with myasthenia gravis. Muscle Nerve 50:443\u2013444","journal-title":"Muscle Nerve"},{"key":"10463_CR14","doi-asserted-by":"publisher","unstructured":"Bonanni L, Dalla Vestra M, Zancanaro A, Presotto F (2014) Myasthenia gravis following low-osmolality iodinated contrast media. Case Rep Radiol. https:\/\/doi.org\/10.1155\/2014\/963461","DOI":"10.1155\/2014\/963461"},{"key":"10463_CR15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4103\/0028-3886.181545","volume":"64","author":"A Khandelwal","year":"2016","unstructured":"Khandelwal A, Shamim R, Supriya (2016) Low \u2013 osmolality contrast agents \u2013 a risk for myasthenics. Neurol India 64:558\u2013559","journal-title":"Neurol India"},{"key":"10463_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13256-019-2114-8","volume":"13","author":"BVKM Bopeththa","year":"2019","unstructured":"Bopeththa BVKM, Hewavithana PB, Hewapathirana HLI, Ralapanawa U (2019) Myasthenic crisis following iodinated contrast material (Iohexol) aspiration: a case report. J Med Case Rep 13:166","journal-title":"J Med Case Rep"},{"key":"10463_CR17","unstructured":"Grading using the Oxford Centre for Evidence Based Medicine (OCEBM) evidence classification (2011) Available via https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Accessed 21 May 2023"},{"key":"10463_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International consensus guidance for management of myasthenia gravis. 2020 update. Neurology 96:114\u2013122","journal-title":"Neurology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-10463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-023-10463-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-10463-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T04:06:00Z","timestamp":1719547560000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-023-10463-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":18,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["10463"],"URL":"https:\/\/doi.org\/10.1007\/s00330-023-10463-z","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Dr. Remy Geenen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare relationships with the following companies:Remy W. F. Geenen: NoneGiles Roditi: NoneMarie-France Bellin: NoneMichele Bertolotto: NoneTorkel B. Brismar: NoneJean-Michel Correas: Bracco Imaging, GuerbetIlona A. Dekkers: NoneGertraud Heinz-Peer: NoneAndreas H. Mahnken: NoneAart J. van der Molen: GuerbetCarlo C. Quattrocchi: Bracco Imaging, Guerbet, Bayer Healthcare, GE HealthcareAlexander Radbruch: NonePeter Reimer: NoneCarmen Sebasti\u00e0: NoneFulvio Stacul: NoneLaura Romanini: NoneOlivier Clement: Bracco Imaging, Guerbet, Bayer HealthcareThe contrast media companies Bayer, Bracco, GE Healthcare, and Guerbet are consultant to the Contrast Media Safety Committee and participate in all scientific discussions, but are not involved in the final recommendations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Basic statistics.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"value":"\u2022 retrospective\u2022 observational\u2022 multicenter study","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}